The ASAM Principles of Addiction Medicine 7th Edition Miller Rosenthal Test Bank is a comprehensive resource designed to support students, clinicians, and healthcare providers in understanding and applying the core principles of addiction medicine. This test bank offers a wide range of questions to assess knowledge of addiction-related topics, including the biology of addiction, clinical assessments, treatment approaches, pharmacotherapy, and the psychosocial aspects of addiction.

1. SECTION 1: Basic Science and Core Concepts
2. 1 Substance Use Disorders: The Neurobiology of Motivation Gone Awry
3. 2 Recommended Use of Terminology in Addiction Medicine
4. 3 The Anatomy of Addiction
5. 4 Clinical Trials in Substance-Using Populations
6. 5 Addiction Medicine Physicians and Collaborative Care Clinicians as Change Agents for Prevention and Public Health
7. 6 Climate Change and Addiction Medicine
8. 7 The Cigarette Industry's Role in Promoting Tobacco Use Disorder
9. 8 The Impact of the Alcohol Industry on Alcohol Use Disorder
10. 9 The Impact of the Cannabis Industry on Cannabis Use Disorder
11. SECTION 2: Pharmacology
12. 10 Pharmacokinetic, Pharmacodynamic, and Pharmacogenomic Principles
13. 11 The Pharmacology of Alcohol
14. 12 The Pharmacology of Nonalcohol Sedative Hypnotics
15. 13 The Pharmacology of Opioids
16. 14 The Pharmacology of Stimulants
17. 15 The Pharmacology of Caffeine
18. 16 The Pharmacology of Nicotine and Tobacco
19. 17 The Pharmacology of Cannabinoids
20. 18 The Pharmacology of Hallucinogens
21. 19 The Pharmacology of Dissociatives
22. 20 The Pharmacology of Inhalants
23. 21 The Pharmacology of Anabolic-Androgenic Steroids
24. 22 Electronic Drug Delivery Devices
25. 23 Novel Psychoactive Substances
26. SECTION 3: Epidemiology And Prevention
27. 24 The Epidemiology of Substance Use Disorders
28. Sidebar Primary, Secondary, and Tertiary Prevention
29. 25 Preventing Substance Use Among Children and Adolescents
30. 26 Environmental Approaches to Prevention: Communities and Contexts
31. 27 Prevention of Prescription Medication Misuse
32. 28 The Harm Reduction Approach to Caring for People Who Use Substances
33. 29 College Student Drinking
34. 30 Policy and Leadership: Impact on Primary, Secondary, and Tertiary Prevention of Substance Use Disorders in Military Personnel and Beyond
35. Sidebar Challenges of Reintegration for Military Personnel and Their Families
36. SECTION 4: Diagnosis, Assessment, And Early Intervention Treatment
37. 31 Screening and Brief Intervention
38. Sidebar 1 Screening and Brief Intervention in Pregnancy
39. Sidebar 2 Screening and Brief Intervention in Trauma Centers, Hospitals, and Emergency Departments
40. Sidebar 3 Implementation of Screening and Brief Intervention in Clinical Settings Using Quality Improvement Principles
41. Sidebar 4 Screening for Unhealthy Alcohol and Drug Use in Older Adults
42. 32 Laboratory Assessment
43. 33 Assessment
44. Sidebar 1 Hospital-Based Addiction Care
45. Sidebar 2 Prevention and Early Treatment in the Workplace Setting
46. 34 Addiction Among Physicians and Physician Health Programs
47. Sidebar Health care Professional Wellness After Patient Overdose Death
48. SECTION 5: Overview Of Addiction Treatment
49. 35 Addiction Medicine in America: Its Birth, Early History, and Current Status (1750-2022)
50. 36 The Treatment of Substance Use Disorders: An Overview
51. 37 Identification and Treatment of High-Risk Alcohol Use and Alcohol Use Disorder: An Overview
52. 38 Race, Ethnicity, Gender, and Social Determinants of Health, Disparities, and Access to Care
53. 39 Cultural Issues in Addiction Medicine
54. 40 Substance Use and Co-occurring Conditions in Women
55. 41 Treatment of Substance Use Disorders in Older Adults
56. 42 Treatment Considerations for LGBTQ Patients
57. 43 Military Sexual Trauma
58. 44 Traumatic Brain Injury and Substance Use Disorders
59. 45 Integrated Care for Substance Use Disorder
60. 46 Substance Use‑Related Care–Interprofessional Collaborative Practice
61. 47 The ASAM Criteria and Matching Patients to Treatment
62. 48 Linking Addiction Treatment With Other Medical and Psychiatric Treatment Systems
63. 49 Reducing Inequities of Care Through Changes in Practice
64. 50 Quality Improvement for Addiction Treatment
65. Sidebar Delivery of Addiction Medicine Care via Video or Phone
66. SECTION 6: Nonsubstance Addiction-Related Disorders
67. 51 Understanding Nonsubstance Addictions
68. 52 Gambling Disorder: Clinical Characteristics and Treatment
69. 53 Compulsive Sexual Behaviors
70. 54 Disorders Associated With Technology and Social Media
71. SECTION 7: Management Of Intoxication And Withdrawal
72. 55 Management of Intoxication and Withdrawal: General Principles
73. 56 Management of Alcohol Intoxication and Withdrawal
74. 57 Management of Sedative-Hypnotic Intoxication and Withdrawal
75. 58 Management of Opioid Intoxication and Withdrawal
76. 59 Management of Stimulant, Hallucinogen, Cannabis, Phencyclidine, and Other Drug Intoxication and Withdrawal
77. SECTION 8: Pharmacological Interventions And Other Somatic Therapies
78. 60 Pharmacological Interventions for Alcohol Use Disorder
79. 61 Pharmacological Interventions for Sedative-Hypnotic Use Disorder
80. 62 Pharmacological Treatment for Opioid Use Disorder
81. Sidebar Medical Director Stewardship of Opioid Treatment Programs
82. 63 Special Issues in Office-Based Opioid Treatment (OBOT)
83. 64 Pharmacological Treatment of Stimulant Use Disorders
84. 65 Pharmacological Interventions for Nicotine and Tobacco Use
85. 66 Pharmacological Interventions for Other Substances and Multiple Substance Use Disorders
86. 67 Complementary and Integrative Interventions for Substance Use Disorders
87. 68 Neuromodulation for Substance Use Disorders
88. SECTION 9: Psychologically Based Interventions
89. 69 Enhancing Motivation to Change
90. 70 Motivational Interviewing
91. 71 Group Therapies
92. 72 Individual Treatment
93. 73 Contingency Management and the Community Reinforcement Approach
94. 74 Behavioral Interventions for Tobacco Use Disorder
95. 75 Network Therapy
96. 76 Therapeutic Communities and Modified Therapeutic Communities for Co-occurring Mental and Substance Use Disorders
97. 77 Aversion Therapies
98. 78 Family Involvement in Addiction, Treatment, and Recovery
99. 79 Twelve-Step Facilitation Approaches
100. 80 Relapse Prevention: Clinical Models and Intervention Strategies
101. 81 Mindfulness-Based Treatment of Addiction
102. 82 Digital Health Interventions for Substance Use Disorders: The State of the Science
103. 83 Medical Management Techniques and Collaborative Care: Integrating Behavioral With Pharmacological Interventions
104. SECTION 10: Mutual Help: Twelve Step And Other Programs In Addiction Recovery
105. 84 Twelve-Step and Other Programs in Addiction Recovery
106. 85 Recent Research Into Twelve-Step Programs
107. 86 Spirituality in the Recovery Process
108. SECTION 11: Medical Disorders And Complications Of Addiction
109. 87 Medical Care of Patients With Unhealthy Substance Use
110. 88 Cardiovascular Disorders Related to Substance Use
111. 89 Liver Disorders Related to Substance Use
112. 90 Renal and Metabolic Disorders Related to Substance Use
113. 91 Gastrointestinal Disorders Related to Substance Use
114. 92 Pulmonary Disorders Related to Substance Use
115. 93 Neurological Disorders Related to Substance Use
116. 94 Human Immunodeficiency Virus, Tuberculosis, and Other Infectious Diseases Related to Substance Use
117. 95 Sleep Disorders Related to Substance Use
118. 96 Traumatic Injuries Related to Alcohol and Other Drug Use
119. 97 Endocrine and Reproductive Disorders Related to Substance Use
120. 98 Substance Use During Pregnancy
121. 99 Perioperative Management of Patients With Substance Use
122. SECTION 12: Co-Occurring Addiction And Other Psychiatric Disorders
123. 100 Substance-Induced Mental Disorders
124. 101 Co-occurring Mood Disorders and Substance Use Disorders
125. 102 Co-occurring Substance Use, Anxiety Disorders, and Obsessive-Compulsive Disorders
126. 103 Co-occurring Psychosis and Substance Use Disorders
127. 104 Co-occurring Attention Deficit Hyperactivity Disorder and Substance Use Disorders
128. 105 Co-occurring Personality Disorders and Substance Use Disorders
129. 106 Co-occurring Posttraumatic Stress Disorder and Substance Use Disorders
130. 107 Co-occurring Eating Disorders and Substance Use Disorders
131. SECTION 13: Pain And Addiction
132. 108 The Pathophysiology of Chronic Pain and Clinical Interfaces With Substance Use Disorder
133. 109 Psychological Issues in the Management of Pain
134. 110 Assessing and Mitigating Risk of Suicide in Patients With Pain and Substance Use Disorders
135. 111 Rehabilitation Approaches to Pain Management
136. 112 Nonopioid Pharmacotherapy of Pain
137. 113 Opioid Therapy of Pain
138. 114 Co-occurring Pain and Substance Use Disorders
139. 115 Legal and Regulatory Considerations in Opioid Prescribing
140. SECTION 14: Children And Adolescents
141. 116 Screening and Brief Intervention for Adolescents
142. Sidebar 1 Neurobiological Determinants of Addiction in Children and Adolescents
143. Sidebar 2 Governmental Policy on Cannabis Legalization and Use: Impact on Youth
144. 117 Assessing Adolescent Substance Use
145. 118 Placement Criteria and Strategies for Adolescent Treatment Matching
146. Sidebar 1 Confidentiality in Caring for Adolescents
147. Sidebar 2 Drug Testing Adolescents in School
148. 119 Treating Substance Use Disorders in Carceral-Involved Youth
149. 120 Treatment of Addiction-Related Disorders in Adolescents
150. 121 Pharmacotherapy for Adolescents With Substance Use Disorders
151. 122 Co-occurring Psychiatric Disorders in Adolescents With Addiction-Related Issues
152. SECTION 15: Ethical, Legal, And Liability Issues In Addiction Practice
153. 123 Ethical Issues in Addiction Practice
154. 124 Consent and Confidentiality Issues in Addiction Practice
155. 125 Clinical, Ethical, and Legal Considerations in Prescribing Medications With Potential for Nonmedical Use and Addiction
156. Sidebar 1: Drug Control Policy: History and Future Directions
157. Sidebar 2: Guidance on the Use of Opioids to Treat Chronic Pain
158. 126 Therapeutic Effectiveness of Cannabis and Cannabinoids
159. Sidebar Legal and Ethical Considerations for Clinicians Recommending Cannabis Used as Treatment
160. 127 Practical Considerations in Drug Testing
161. Sidebar Workplace Drug Testing and the Role of the Medical Review Officer
162. 128 Reducing Substance Use in Court-Leveraged Treatment
163. Sidebar Reducing Disparities in Substance Us